What has proven to be a long and challenging regulatory journey appears to be approaching its final destination as Medizone has filed what is expected to be its final EPA submission.
What places AsepticSure® in a league by itself lies not only in its ability to achieve remarkable levels of room disinfection within a busy time-sensitive hospital environment, but the fact that it utilizes a new “green” technology that meets all international safety standards without damaging the environment or leaving residual chemicals behind. It achieves this in both a time and cost-effective manner. The fact that AsepticSure comfortably meets the U.S. Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit TWA (PEL-TWA), the American Conference of Governmental Industrial Hygienists (ACGIH®) Threshold Limit Value TWA (TLV®-TWA), and the U.S. Environmental Protection Agency (EPA) National Ambient Air Quality Standards (NAAQS) is noteworthy. The ultimate approval by the EPA as a room disinfectant will bring this system through the gates to continent-wide commercial success. AsepticSure establishes a previously unobtainable level of disinfection efficacy and is proving to be a time efficient technology inside hospital workflows. Data to date demonstrates significantly reduced new infection rates, resulting in economic savings to the medical system through avoidance of the treatment costs associated with hospital acquired infections (HAI).
Working in conjunction with highly experienced regulatory advisors from Washington and Virginia, our team at Innovation Park, Queen’s University believe we have successfully met all of the registration requirements of the agency, including those challenges referred to in the May 6th shareholder communication posted on our website.
EPA now has 21 days to conduct a preliminary review for any possible deficiencies, after which the formal review will commence.